Northwire Canada EditionTuesday, July 14, 2026
Northwire
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%
Financings

Onco-Innovations closes $1.21M private placement

ONCO · Price

Executive Summary

  • Onco-Innovations Ltd. has closed its previously announced non-brokered private placement, raising aggregate gross proceeds of $1,215,500.
  • The company issued 1.87 million units at a price of 65 cents per unit, with each unit consisting of one common share and one common share purchase warrant.
  • Proceeds are designated for general corporate and working capital purposes, including operational, R&D, and investor relations objectives.

Key Details

  • Units Issued: 1.87 million units.
  • Price Per Unit: 65 cents.
  • Gross Proceeds: $1,215,500.
  • Warrant Terms: Each unit includes one common share purchase warrant. Each warrant entitles the holder to purchase one additional share at an exercise price of 75 cents.
  • Warrant Expiration: March 12, 2029 (three-year term from closing).
  • Use of Proceeds: General corporate and working capital purposes, specifically for operational, research and development, and investor relations objectives.
  • Administrative Services: The company issued 18,700 shares to an arm's-length third party as consideration for administrative services rendered in connection with the private placement.
  • Statutory Hold: All securities are subject to a statutory hold period of four months and one day.
  • Previous Announcements: This closing relates to announcements dated January 23, 2026, and an amendment dated February 12, 2026.
Read the original news release →

More from Onco-Innovations Ltd